E. RICHARD GOLD

|  |
| --- |
| Dr. Richard Gold is a James McGill Professor at McGill University’s Faculty of Law where he was the founding Director of the Centre for Intellectual Property Policy. He teaches in the area of intellectual property and innovation. His research centers on the nexus between innovation, development and commerce, particularly with respect to biotechnology. Professor Gold has provided advice to Health Canada, Industry Canada, the Canadian Biotechnology Advisory Committee, the Ontario Ministry of Health and Long-Term Care, the Organisation for Economic Cooperation and Development (where he was the lead author of the OECD Guidelines on the Licensing of Genetic Inventions and a report on Collaborative Mechanisms in Life Science Intellectual Property), the World Health Organization, the World Intellectual Property Organization and UNITAID. His research has been supported by the Social Sciences and Humanities Research Council, the Canadian Institutes of Health Research, Genome Canada, the National Centres for Excellence and the National Institutes of Health. He is a Research Associate at the Health Law Institute at the University of Alberta and was a Jean Monnet Fellow at the European University Institute. His research has been published in high-impact journals in science, law, philosophy, international relations including Nature Biotechnology, The Lancet, PLoS Medicine, the McGill Law Journal, Public Affairs Quarterly, International Studies Quarterly and the European Journal for International Relations.Le Professeur Richard Gold enseigne dans les domaines de la propriété intellectuelle et de l'innovation à la Faculté de droit de l'Université McGill, où il a par ailleurs été parmi les fondateurs (et premier directeur) du Centre des politiques en propriété intellectuelle. Ses travaux de recherche se concentrent sur les liens entre innovation, développement et commerce, notamment dans le domaine des biotechnologies. Le Professeur Gold a conseillé Santé Canada, Industrie Canada, Le Comité consultatif canadien sur les biotechnologies, le ministère ontarien de la Santé, l'Organisation pour la coopération et le développement économique (il est l'auteur principal des Lignes directrices de l'OCDE relatives aux licences sur les inventions génétiques et  du rapport sur les mécanismes collaboratifs de la propriété intellectuelle dans le domaine des sciences de la vie), l'Organisation mondiale de la santé, l'Organisation mondiale de la propriété intellectuelle et UNITAID. Ses travaux de recherche sont financés par le CRSH, les IRSC, les RCE et les NIH. Il est chercheur associé au Health Law Institute de l'Université de l'Alberta et fut Jean Monnet fellow à l'Institut Universitaire Européen. Ses travaux ont été publiés dans d'importantes revues dans le domaine des sciences, du droit, de la philosophie et des relations internationales telles que Nature Biotechnology, The Lancet, PLoS Medicine, la revue de droit de McGill, Public Affairs Quarterly, International Studies Quarterly, et le European Journal for International Relations. |
| **EMPLOYMENT** |  |
| **2015-present****2011-present****2010- 2011****2001-2010** | **Faculty of Law, McGill University** (Montreal)One of the world’s leading law faculties with a unique transsystemic legal teaching program**Associate Dean, Graduate Studies*** Responsible for recruitment and admission of graduate students at the Faculty of Law
* Supervise Graduate Office staff and budget of more than $1.1 million
* Leading effort to review and revise the Faculty’s LLM programmes and add structure to its DCL program

**James McGill Professor*** Teaches courses innovation, property, intellectual property and patent theory and policy at McGill
* Senior Fellow, Centre for International Governance Innovation (since 2016)
* Taught comparative industrial property at Sciences Po (Paris)
* Chair, Open Science Evaluation Committee, Montreal Neurological Institute from 2016
* Member, Board of Directors, Green Aviation Research & Development Network (GARDN) from 2015
* Chair, Knowledge and Technology Exploitation Committee, BioFuelNet from 2013
* Member, Intellectual Property Institute of Canada, Biotechnology Patents Committee and International Trade Committee, 2015-present
* Chair, Intellectual Property Appeals Committee, 2013-present
* Member, Statutory Selection Committee, 2013-present
* Member, Committee on the Rights of Senate, 2016-present
* Member of McGill’s Centre for Intellectual Property Policy
* Member of McGill’s Centre of Genomics and Policy
* Member, McGill University Senate
* Associate Member, Department of Human Genetics, Faculty of Medicine
* Member, Stem Cell Oversight Committee, Canada Health Institutes of Health 2013-2015
* Member of Quartier d’Innovation Committee 2011-2012

**Faculty of Law, McGill University** (Montreal)**Full Professor*** Taught courses in property, tort and innovation at McGill on patents at Sciences Po (France), and on eco-patents at the UniverSud (Paris)
* Holder of the Gide Loyrette Nouel Chair to visit Sciences Po (Paris) in 2011
* Member of McGill University’s Transformation Research and Innovation Committee
* Member of McGill’s Centre of Genomics and Policy
* Associate Member, Department of Human Genetics, Faculty of Medicine

**Faculty of Law, McGill University****Associate Professor*** Chair of the International Expert Group on Biotechnology, Innovation and Intellectual Property that released its landmark report and case studies in the fall of 2008 around the world
	+ Report and case study among top 10 downloaded documents from SSRN in September 2008-10-24
	+ Led to significant media coverage on every continent
	+ Policy and media briefings in Canada, the UK, the US, France and Mali
* Received largest ever grant from the Social Sciences and Humanities Research Council in Canada for work on biotechnology and intellectual property and among the highest grant recipients at the Faculty of Law
* Published peer-reviewed articles, book chapters and government reports in law, science, management and public affairs
* Taught courses on patent law, intellectual property law, property law and innovation at McGill, Sciences Po (France) and University de Paris V (France)
* Significant supervision of post-doctoral fellows, doctoral, masters and undergraduate students
* Frequent speaker on intellectual property, innovation and biotechnology internationally
* Chair of a Committee on Research Misconduct, 2010
* Member of NSERC Expert Group on IP, Council of Canadian Academies Expert Group on Nanotechnology, NSERC/CIHR/SSHRC peer review committee for the Intellectual Property Mobilization programme
* Significant contribution to Faculty and University committees and administration
 |
| **2008-2013** | **The Innovation Partnership** (Montreal)A non-profit consulting firm dedicated to the better use and management of intellectual property in developed and developing countries**President*** Establish strategy for the organisation, including the selection and negotiation of projects
* Develop communication and media relations in respect of the organisation and its work
* Network and develop projects in conjunction with the management team
* Supervise a team of three managers and a dozen experts
* Lead author on a study for **UNITAID** on legal issues relating to the implementation of an Essential Medicines Patent Pool
* Supervised project reviewing intellectual property policies for the **Canadian Breast Cancer Foundation**
* Provided policy advice and drafted report for **Health Canada** on technology transfer and on mechanisms to ensure accessibility of genetic inventions
* Supervised project on technology transfer at institutions of higher education for **Industry Canada**
* Created a training program in Eastern Africa for senior scientists and policy-makers on intellectual property management
 |
| **2003-2008** | **Centre for Intellectual Property Policy, McGill University** (Montreal)A leading international research centre focusing on research, capacity-building and developing a global conversation on the role of intellectual property in innovation and development**Founding Director*****Management Responsibilities:**** Strategy, research leadership, external communication and network-building resulting in the Centre becoming a leader in intellectual property policy within its four three years
* Grant writing and fundraising leading to the award, as Principal Investigator, of the largest grant (Cdn$3 million) ever provided by the Social Science and Humanities Research Council of Canada and 8 other grants (as PI or Co-Applicant) including 2 from the Canadian Institutes for Health Research, 2 from Genome Canada, 1 from the National Centres for Excellence and 1 from the Foundation for Sustainable Enterprise and Development for total annual budget of approx. Cdn$1 million
* Communication and outreach to policy communities (foundations, governments, industry) leading to the development of national and international research projects and partnerships
* National and international media relations leading to publication of interviews and opinion articles
* Managing a team of 25+ researchers from 8 disciplines, students and 3 staff members
* Managing conference and workshop organisation leading to one international conference and 6 international workshops

***Research Responsibilities:**** Developed innovative research and outreach methodology to coordinate the input of individuals from different disciplines
* Supervised and drafted policy reports, including for the **World Health Organization** and the **Canadian Biotechnology Advisory Committee**
 |
| **2000-2016** | **Policy Consultant*** Drafted the OECD Council Guidelines on the Licensing of Genetic Inventions as Consultant to **Organisation for Economic Co-operation and Development** (2003-05)
* Acted as Consultant to the **World Intellectual Property Organization** on health-related IP in Indonesia (2004-05)
* Was Legal Policy Advisor to the **Ontario Ministry of Health & Long-Term Care** leading to a report on genetic inventions and litigation in the Supreme Court of Canada (2001-2003)
* Acted as Senior Advisor to the **Canadian Biotechnology Advisory Committee** leading to the publication of a report on the patenting of higher life forms (2000-01)
 |
| **1997-2001** | **Faculty of Law, University of Western Ontario**(London, ON)Faculty with specific focus on business-related law**Assistant Professor*** Taught *Common Law Property; Company Law;* and *Advising a New Economy Business*
* Prepared and participated in 7 successful grant applications as Principal Investigator or Co-Applicant
* Prepared and published over 12 monographs, peer-reviewed journal articles and book chapters
* Taught courses at the Université de Montpellier (1999) and the University of Puerto Rico (1999)
 |
| **1990, 1993-97** | **Torys** (Toronto) A leading Canadian law firm in corporate-commercial law**Associate, Technology Practice Group*** Founding associate of the Technology Practice Group, supervising and training over a dozen associates
* Involved in corporate-commercial transactions related to technology outsourcing, strategic alliances and joint ventures, financing of technology companies, licensing and mergers and acquisitions
 |
| **1990-91** | **Supreme Court of Canada** (Ottawa)**Clerk to Hon. Mr. Justice Peter deC. Cory** |
| **1988-89** | **Ontario Court of Appeal** (Toronto)**Law Clerk to the Chief Justice and Justices of the Court of Appeal** |
| **EDUCATION AND QUALIFICATIONS** |  |
| **1992-95** | **University of Michigan Law School****Doctor of Laws (S.J.D.)*** Prepared thesis entitled *Body Parts: Property Rights and the Ownership of Human Biological Materials* later published by Georgetown University Press (Washington) in 1996
 |
| **1991-92** | **University of Michigan Law School****Master of Laws (LL.M.)** |
| **1990** | **Law Society of Upper Canada****Call to the Bar of Ontario** |
| **1985-88** | **Faculty of Law, University of Toronto****Bachelor of Laws (Honours)*** Dean’s Honour List and prizes in Property Law, Torts, Civil Liberties, writing and academic excellence
 |
| **1981-84** | **Faculty of Science, McGill University****Bachelor of Science (Computer Science and Mathematics)*** Significant entry scholarship
* Graduated with great distinction and various awards
 |
| **FELLOWSHIPS** |  |
| **2016-Present****2000-Present** | **Centre for International Governance Innovation**A legal independent Canadian think-tank that examines issues related to innovation, the environment and international governance**Health Law Institute, University of Alberta**Leading Canadian research institute on health, biotechnology and commercialisation**Research Associate** |
| **2003** | **Robert Schuman Centre for Advanced Studies, European University Institute** (Florence)One of the leading interdisciplinary centres with a specific focus on international relations and politics in Europe**Jean Monnet Fellow*** Developed a transdisciplinary research methodology on biotechnology intellectual property leading to a publication in *Public Affairs Quarterly*
 |
| **2000-2002** | **Einstein Institute for Science, Health and the Courts**US institute developing and providing training to judges **Senior Fellow** |

**APPENDIX A**

**PUBLICATIONS**

PART I: PEER REVIEWED PUBLISHED AND FORTHCOMING WORKS

***Monograph:***

1. **Gold, E. Richard,** *Body Parts: Property Rights and the Ownership of Human Biological Materials* (Washington, D.C.: Georgetown University Press, 1996).

***Edited Monograph:***

1. Bubela, Tania and **E. Richard Gold***, Genetic Resources and Traditional Knowledge: Case Studies and Conflicting Interests* (Cheltenham: Edward Elgar, 2012).
2. **Gold, E. Richard** and Bartha Maria Knoppers, eds, *Biotechnology IP & Ethics*, (Toronto: LexisNexis, 2009). Lead editor and author of one chapter.

***Peer Reviewed Journals:***

1. **Gold, E. Richard**, Morin, Jean-Frédéric, Shadeed, Erica, “Does Intellectual property Lead to Economic Growth? Insights from an Improved IP Dataset”, (forthcoming), *Regulation & Governance*.
2. Bubela, Tania, Bonter, Katherine, Lachance, Silvy, Delisle, Jean-Sébastien, and **Gold, E. Richard**, “More Haste, Less Speed: Could Public-Private Partnerships Advance Cellular Immunotherapies?”, (forthcoming), *Frontiers in Medicine.*
3. Ali-Khan, Sarah E. and **Gold, E. Richard**, “Gene patents still alive and kicking: their impact on provision of genetic testing for long QT syndrome in the Canadian public health-care system”, (2017) *Genetics in Medicine* doi:10.1038/gim.2017.43
4. **Gold, E. Richard**, “Accelerating Translational Research through Open Science: The Neuro Experiment”, (2016) *PLoS Biology* <http://dx.doi.org/10.1371/journal.pbio.2001259>
5. Morin, Jean-Fréderic and **E. Richard Gold**, “International socialization at the state and individual levels: mixed evidence from intellectual property”, (2016), *Cambridge Review of International Affairs.* http:/dx.doi.org/10.1080/09557571.2016.1230734.
6. Bubela, Tania and **E. Richard Gold**, “Cell Therapy Licensing: A Web for the Unwary in *Kimble v. Marvel Entertainment*”, (2016), *Regenerative Medicine,* doi: 10.2217/rme.15.86
7. Rivoire, Maxence and **E. Richard Gold**, “Propriété intellectuelle, Cour Suprême du Canada et droit civil” (2015) 60:3 *McGill Law Journal,* 381-430.
8. Grant, Emily, Megan Van de Hof and **E. Richard Gold**, “Patent landscape analysis: A methodology in need of harmonized standards of disclosure” (2014) 39 *World Patent Information*, 3-10.
9. **Gold, E. Richard** and Michael Shortt, “The Promise of the Patent in Canada and Around the World” (2014) 30:1 *Canadian Intellectual Property Review*, 35-77.
10. Morin, Jean-Frederic and **E. Richard Gold**, “An Integrated Model of Legal Transplantation: The Diffusion of Intellectual Property Law in Developing Countries” (2014) 58 *International Studies Quarterly* 781-792.
11. **Gold, E. Richard**, Robert Cook-Deegan, and Tania Bubela, “AMP v Myriad: A Surgical Strike Against Blockbuster Business Models” (2013) 5:192 *Science Translational Medicine*, 1-2.
12. **Gold, E. Richard**, “Patents and Human Rights: A Heterodox Analysis” (2013) 41:1 *Journal of Law, Medicine and Ethics,* 185-198.
13. Bubela, Tania, **E. Richard Gold**, Gregory D. Graff, Daniel R. Cahoy, Dianne Nicol, and David Castle, “Patent Landscaping for Life Sciences Innovation: Toward Consistent and Transparent Practices” (2013) 31 *Nature Biotechnology,* 202-206.
14. **Gold, E. Richard** and Andrew Baker, “Evidence-Based Policy: Understanding the Technology Landscape” (2012) 22:1 *Journal of Law, Information and Science*, 76-97.
15. **Gold, E. Richard** and Robert Carbone, “(Mis)Reliance on Social Science Evidence in Intellectual Property Litigation: A Case Study” (2012) 28:2 *Canadian Intellectual Property Review*, 179-196.
16. **Gold, E. Richard** and Jean-Frederic Morin, “Promising Trends in Access to Medicines” (2012) 3:2 *Global Policy,* 231-237.
17. **Gold, E Richard**, “Patenting of Genes: Discoveries or Inventions?” (2012) in *eLS*. John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0005183.pub2
18. Bubela, Tania, G.A. FitzGerald, **E. Richard Gold**, “Recalibrating intellectual property rights to enhance translational research collaborations” (2012) 4:122 *Science. Translational Medicine,* 122cm3.
19. Morin, Jean-Frederic, Kevin Daley, and **E. Richard Gold**, “Having Faith in IP: Empirical Evidence of IP Conversions” (2011) 3:1 *WIPO Journal*, 93-102.
20. Bubela, Tania, **E. Richard Gold** and Jean-Frederic Morin, **“Wicked Issues for Canada at the Intersection of Intellectual Property and Public Health: Mechanisms for Policy Coherence” (2011) 4:2 *McGill Journal of Health Law*, 3-41. This article was based on a project that I supervised.**
21. Morin, Jean-Frederic and **E. Richard Gold**, “Consensus-Seeking, Distrust, and Rhetorical Entrapment: The WTO Decision on Access to Medicines” (2010) 16:4 *European Journal of International Relations,* 563-587. Second author of this article prepared by my post-doctoral fellow.
22. Carbone, Julia, **E. Richard Gold**, Bhaven Sampat, Subhashini Chandraskharan, Lori Knowles, Misha Angrist, and Robert Cook-Deegan, “DNA patents and diagnostics: not a pretty picture” (2010) 28:8 *Nature Biotechnology,* 784-791. This article arose out of a workshop that I co-sponsored with Robert Cook-Deegan.
23. **Gold, E. Richard**, & Julia Carbone, “Response to Dr. Palombi” (2010) 12:7 *Genetics in Medicine,* 471-472. I conceived and prepared this letter.
24. **Gold, E. Richard**, & Julia Carbone, “Myriad Genetics: In the eye of a policy storm” (2010) 12:4 *Genetics in Medicine*, S39-S70. I was lead author on this article that was prepared under a grant on which I was Principal Investigator.
25. **Gold, E. Richard**, Warren Kaplan, James Orbinski, Sarah Harland-Logan, Sevil N-Marandi, “Are Patents Impeding Medical Care and Innovation?” (2010) 7:1 *PLoS Med*: e1000208. I prepared one of three related opinions that were published together.
26. **Gold, Richard**, "Avoiding the Mistakes of Biotech: How Intellectual Property Can Be Better Managed to Advance Nanotechnology Research" (2009) 3:3 *Studies in Ethics, Law, and Technology*.
27. **Gold, E. Richard** and Jean-Frederic Morin, “The missing ingredient in medicine patent pools” (2009) 374:9698 *The Lancet,* 1329-1330. This letter was jointly prepared by me and my post-doctoral fellow.
28. **Gold, E. Richard**, Tania Bubela, Fiona Miller, Dianne Nicol, and Tina Piper, “Gene patents – more evidence needed, but policymakers must act”(2007) 25 *Nature Biotechnology,* 388-389. I was lead author on this letter responding to an article in Nature Biotechnology.
29. **Gold, E. Richard**, “Intellectual architecture as place brand”(2006) 2 *Place Branding*, 220-228.
30. **Gold, E. Richard**  & Karen L. Durell, “Innovating the Skilled Reader: Tailoring Patent Law to New Technologies” (2005) 19:1 *Intellectual Property Journal*, 189
31. **Gold, E. Richard**, Wendy Adams, David Castle, Ghislaine Cleret de Langavant, L. Martin Cloutier, Abdallah S. Daar, Amy Glass, Pamela J. Smith, and Louise Bernier, “The Unexamined Assumptions of Intellectual Property: Adopting an Evaluative Approach to Patenting Biotechnological Innovation” (2004) 18:4 *Public Affairs Quarterly,* 299-344.
32. **Gold, E. Richard**, “TheReach of Patent Law and Institutional Competence” (2004) 1 University of Ottawa Law and Technology Journal, 263-284.
33. Smith, Richard D, Halla Thorsteinsdóttir, Abdallah S. Daar, Peter A. Singer, and **E. Richard Gold**, “Equity and Genomics Knowledge: A 'Global Public Good' Perspective of the Patent System” (2004) 82:5 *World Health Organization Bulletin,* 385-389. I was one of several authors on this article prepared under a project headed by Peter Singer.
34. **Gold, E. Richard**, “SARS genome patent: symptom or disease?” (2003) 361:9374 *The Lancet,* 2002-2003. (invited article).
35. Caulfield, Timothy A, Bartha M Knoppers, **E. Richard Gold**, Lorraine E Sheremeta, and Peter J Bridge, (2003) 63:1 “Genetic technologies, health care policy and the patent bargain” *Clinical Genetics,* 15-18. I was one of several authors on this article.
36. **Gold, E. Richard** and Daniel Lam, “Balancing Trade in Patents: Public Non-Commercial Use and Compulsory Licensing” (2003) 6:1 The Journal of World Intellectual Property, 5-31. This article was prepared under a project under which I was Principal Investigator.
37. **Gold, E. Richard**, “From Theory to Practice: Health Care and the Patent System” (2003) Special Edition 2003 *Health Law Journal,* 21-40.
38. **Gold, E. Richard** and Wendy Adams, “Reconciling Private Benefit and Public Risk in Biotechnology: Xenotransplantation as a Case Study in Consent” (2002) 10 *Health Law Journal* 31-75. This article was prepared under a project under which I was Principal Investigator.
39. **Gold, E. Richard**and Caulfield, Timothy, “The moral tollbooth: a method that makes use of the patent system to address ethical concerns in biotechnology” (2002)359(9325) *The Lancet* 2268-2270.
40. **Gold, E. Richard*,*** Timothy Caulfield, and Peter Ray, “Gene Patents and the Standard of Care” (2002)167:3 *Canadian Medical Association Journal*, 256-257.
41. **Gold, E. Richard*,*** David Castle, L. Martin Cloutier, Abdallah S. Daar, and Pamela J. Smith, “Needed: Models of Biotechnology Intellectual Property” (2002) 20:8 *Trends in Biotechnology,* 327-329. This article was written as part of a project on which I was Principal Investigator.
42. **Gold, E. Richard,** “Gene Patents and Medical Access” (2002) 49 *Intellectual Property Forum,* 20-27.
43. **Gold, E. Richard** and Alain Gallochat, “The European *Biotech Directive*: Past As Prologue” (2001) 7:3 *European Law Journal,* 331-366.
44. **Gold, E. Richard** “Biotechnology patents: strategies for meeting economic and ethical concerns” (2001) 30 *Nature Genetics,* 359.
45. **Gold, E. Richard** and Adams, Wendy, “The *Monsanto* Decision: the edge or the wedge” (2001)19 *Nature Biotechnology,* 587.
46. **Gold, E. Richard** “Finding Common Cause in the Patent Debate” (2000)18 *Nature Biotechnology,* 1217 (comment).
47. **Gold, E. Richard**, “Moving the Gene Patent Debate Forward” (2000) 18 *Nature Biotechnology*, 1319 (comment).
48. Caulfield, Timothy A., **E. Richard Gold**and Cho, Mildred, “Patenting Human Genetic Material: Refocusing the Debate” (2000)1:3 *Nature Reviews Genetics,* 227-231.
49. Caulfield, Timothy A. and **E. Richard Gold**, “Genetic Testing, Ethical Concerns, and The Role of Patent Law” (2000)57:5 *Clinical Genetics,* 370-375.
50. **Gold, E. Richard,** “Biomedical Patents and Ethics: A Canadian Solution” (2000) 45:2 *McGill Law Journal,* 413-435.
51. **Gold, E. Richard,** “Partial Copyright Assignments: Safeguarding Software Licensees Against the Bankruptcy of Licensors” (2000) 33 *Canadian Business Law Journal*, 193.
52. **Gold, E. Richard**, “Hope, Fear, and Genetics: Judicial Approaches to Biotechnology” (1999)83 *Judicature*, 132**.**
53. **Gold, E. Richard**, “Owning our bodies: An Examination of Property Law and Biotechnology” (1995) 32:4 *San Diego Law Review*, 1167.
54. **Gold, E. Richard** “A Structural Dynamic Theory of Law” (1991) 16 *Queen’s Law Journal*, 347.
55. **Gold, E. Richard**, “From Right to Remedy: Putting Equality to Work” (1989) 12 *Queen’s Law Journal,* 214.

***Peer Reviewed Book Chapters:***

1. **Gold, E. Richard**, “Legal Foundations of the U.S. Dollar, 1933-1934 and 1971” in *Orderly Change: International Monetary Relations since Bretton Woods*, ed David Andrews (Ithaca: Cornell University Press, 2008), 177-188.
2. **Gold, E. Richard**, “Exclusive Rights in Life: Biotechnology, Genetic Manipulation, and Intellectual Property Rights” in *Molecular Methods of Plant Analysis,* ed JF Jackson, HF Linskens, RB Inman (Heidelberg: Springer-Verlag, 2003), 1-22.
3. **Gold, E. Richard,**“Genes and patents: discoveries or inventions?” in *Encyclopedia of the Human Genome,* ed David Cooper (London: Nature Publishing Group, 2003).
4. **Gold, E. Richard,** “Merging Business And Ethics: New Models For Using Biotechnological Intellectual Property” in *Genetically Modified Foods: Debating Biotechnology*, ed Michael Ruse and David Castle (New York: Prometheus Press, 2002), 163.
5. **Gold, E. Richard,** “Health Care Reform and International Trade” in *Health Care Reform in Canada and the Law in Canada – Meeting the Challenge*, ed Timothy A Caulfield and Barbara von Tigerstrom (Edmonton: University of Alberta Press, 2002), 223-244.

***Peer Reviewed Government Commissioned Papers:***

1. Gold, E. Richardand Alain Gallochat, “EU Directive For The Legal Protection Of Biotechnological Inventions: An Analysis Of Its Key Sections, Implementation History And Lessons For Canada” (2001) for the Canadian Biotechnology Advisory Committee.
2. Gold, E. Richard, “Patenting Life Forms: An International Comparison” (2001) for the Canadian Biotechnology Advisory Committee.
3. Gold, E. Richard, “Patents in Genes” (2001) for the Canadian Biotechnology Advisory Committee.

## PART II: OTHER PUBLISHED WORKS

***Journal/Online articles:***

1. **Gold, E. Richard**, “The Midas Conundrum” (April 25, 2017) in Centre for International Governance Innovation Series on Innovation and Productivity, <https://www.cigionline.org/articles/midas-conundrum>.
2. **Gold, E. Richard**, “Why Women Over 40 are Having More Babies” (March 16, 2017) <https://www.cigionline.org/articles/why-women-over-40-are-having-more-babies>.
3. **Gold, E. Richard**, “New genetic testing deal could spur major research breakthroughs” (May 18, 2016) *Healthy Debate* http://healthydebate.ca/opinions/cheo-genetic-testing-agreement
4. **Gold, E. Richard**, Samuel Abraham, Ann Gualtieri, and Iain M. Gillespie, “Innovating a Canadian Innovation Ecosystem” (July-August 2015) *Policy Options,* 27-29.
5. **Gold, E. Richard**, “Response to *Law of the Body* by Meredith M. Render” (2014) 63 *Emory Law Journal* *Online*, 2011-2019.
6. **Gold, E. Richard**, “Biotechnological Innovation and Partnerships” (2009) 10 *Journal of High Technology Law*, 1.
7. **Gold, E. Richard, “**Innovation and Productivity: The need for an intellectual architect” (October 2006) *Policy Options,* 75-78.
8. **Gold, E. Richard**, Joly, Yann and Caulfield, Timothy A., “Genetic Research Tools, the Research Exception and Open Science” (2005) 3:2 GenEdit, online: http://www.humgen.umontreal.ca/int/genedit.cfm?idsel=1313**.**
9. Caulfield, Timothy A. and **E. Richard Gold**, “Whistling in the Wind” (2000) 15:1 *FORUM for Applied Research and Public Policy,* 75-79.
10. **Gold, E. Richard,** “Sir Lyman Duff and the Fork in the Road” (1988) 46:2 *University of Toronto Faculty of Law Review*, 424.

***Videos***

1. **Gold, Richard**, “Putting Innovation in Context” (February 8, 2007) https://www.cigionline.org/multimedia/putting-innovation-context

# *Book Chapters*

1. van Zimmeren, E., Nicol, D., **Gold, E.R.**, Carbone, J, Chandrasekharan, S., Baldwin, A.L., and Cook-Deegan, R., “The BRCA Patent Controversies: An international review of patent disputes” in *Breast Cancer Gene Research and Medical Practices: Transnational Perspectives in the Time of BRCA*, eds Gibbon, S, Joseph, G, Mozersky, J, zur Nieden, A, and Palfner, S. (London: Routledge, 2014), 151-174.
2. **Gold, E. Richard** and Dianne Nicol, “Beyond Open Source: Patents, Biobanks and Sharing” in *Comparative Issues in the Governance of Research Biobanks,* edsGiovanni Pascuzzi, Umberto Izzo, and Matteo Macilotti (New York: Springer, 2013), 191.
3. Nicol, Dianne and **E. Richard Gold**, “Standards for Biobank Access and Intellectual Property” in *Intellectual Property and Emerging Technologies*, ed Matthew Rimmer and Alison McLennan (New York: Edward Elgar, 2012), 133-157.
4. **Gold, E. Richard** and Tal Srulovicz, “Beyond Economics: Cultural and Institutional Barriers to Commercializing Innovation” in *Perspectives on Commercializing Innovation,* edF. Scott Kieff and Troy A. Paredes (Cambridge: Cambridge University Press, 2011), 560.
5. **Gold, E. Richard** and Karen Durell, “Looking Beyond the Firm: Intellectual Asset Management and Biotechnology” in *The Role of Intellectual Property Rights in Biotechnology Innovation,* ed David Castle. (New York: Edward Elgar, 2009), 133-152.
6. **Gold, E. Richard** and Jean-Frederic Morin, “From Agenda to Implementation: Working Outside the WIPO Box” in *Implementing the World Intellectual Property Development Agenda*, ed Jeremy de Beer (Ottawa: International Development Research Centre, 2009), 57.
7. **Gold, E. Richard**, “Commentary: Mending the Gap – Intellectual Property, Competition Law, and Compulsory Licensing” in *Competition Policy and Intellectual Property*, ed Marcel Boyer, Michael Trebilcock and David Vaver (Toronto: Irwin Law, 2009), 396.
8. **Gold, E. Richard**, “The Ethics of Biotechnological Intellectual Property” in *Biotechnology IP & Ethics*, ed E. Richard Gold and Bartha Maria Knoppers (Toronto: LexisNexis, 2009), 15.
9. **Gold, E. Richard,** “Biotechnology and Boundary Busting: Legal Challenges in the Biotech Era” in *Life, Technology and Law,* ed Carlo Casanato (Verona: CEDAM, 2007).
10. **Gold, E. Richard** and David Castle, “Traditional knowledge and benefit sharing: from compensation to transaction” in *Accessing and Sharing the Benefits of the Genomics Revolution,* edP. Phillips and C. Onwuekwe (Dordrecht: Springer, 2007).
11. **Gold, E. Richard** and L. Karen Durell, “Comparative Intellectual Property Issues in Biotechnology” in *Food, Health and Biotechnology: Consumer and Social Issues in Canada’s New Food and Health Product Industries,* ed Nola M. Ries & Jacob J. Shelley (Victoria: AFMNet, 2007).
12. **Gold, E. Richard** and Tania Bubela, “Drafting Effective Collaborative Research Agreements and Related Contracts” in *Intellectual Property Management in Health and Agricultural Innovation: A Handbook of Best Practices*, ed A Krattiger, RT Mahoney, L Nelson, et al. (Oxford: MIHR, 2007), available online at [www.ipHandbook.org](http://www.ipHandbook.org).
13. **Gold, E. Richard**, David Castle, and L. Martin Cloutier, “Agrobiotecnologianos Tribunais: Patentes, Privilegios e Presuncoes” in *Propriedade Intelectual,* ed Edson Rodrigues Jr., & Fabricio Polido (Rio de Janeiro: Elsevier, 2007), 275.
14. Caulfield, Timothy, Lorraine Sheremeta, **E. Richard Gold**, Jon Merz, and David Castle, “Informing Genomic Patent Policy” in *Genetic Testing: Care, Consent and Liability*, ed Neil F. Sharpe and Ronald F. Carter (New York: John Wiley & Sons, 2006).
15. Cloutier, L. Martin and **E. Richard Gold,** “A Legal Perspective on Intellectual Capital” in *Perspectives on Intellectual Capital: Multidisciplinary insights into management, measurement, and reporting*, ed B. Marr (Boston: Elsevier, 2005).
16. **Gold, E. Richard,** “The Diversity of Intellectual Properties” in *Human Diversity and the Law*, ed Mauro Bussani and Michele Graziadei (Brussels: Bruylant Ltd., 2005).
17. Caulfield, Timothy A., Bartha Maria Knoppers, **E. Richard Gold**, Lorraine E. Sheremeta, and Peter J. Bridge, “Genetic Technologies, Health Care Policy and the Patent Bargain” in *Genomics, health and Society: Emerging issues for public policy*, ed Bartha Maria Knoppers and Charles Scriver (Ottawa: Public Research Initiative, 2004).
18. **Gold, E. Richard,** “Making Room: Reintegrating Basic Research, Health Policy, and Ethics Into Patent Law” in *The Commercialization of Genetic Research*, ed Timothy A. Caulfield and Bryn Williams-Jones (New York: Plenum Publishers, 1999), 63.

# *Policy Reports*

1. **Gold, E. Richard**,*Collaborative Mechanisms for Intellectual Property Management in the Life Sciences* (2011). A Report for the Organisation for Economic Co-operation and Development.
2. Callan, Benedict, Tania Bubela, Barbara Slater, Marc-Andre Gagnon, Melanie Bourassa Forcier, and E. Richard Gold, *Impact of Intellectual Property Protection on Pharmaceutical Innovation (2011). A Report for Health Canada*
3. Gagnon, Marc-Andre and E. Richard Gold, Public Financial Support to the Canadian Brand-name Pharmaceutical Sector: A Cost-Benefit Analysis (2011). A Report for Health Canada.
4. De Beer, Jeremy de Beer, **E. Richard** **Gold,** and Mauricio Guaranga, *GPS Policy Brief No. 4: Intellectual Property Management: Policy Issues and Options* (2011). A Report for Genome Canada.
5. Bently, Lionel, Brad Sherman, Denis Borges Barbosa, Shamnad Basheer, Conrad Visser, & **E. Richard Gold,** *Exclusions from Patentability and Exceptions and Limitations to Patentees’ Rights* (2010) A Study Prepared for the World Intellectual Property Organization, Standing Committee on the Law of Patents.
6. **Gold E. Richard**, Bubela, Tania, Carbone Julia, et al. *At the intersection of health and intellectual property: Issues, tools and directions for Health Canada* (2010) Report to Health Canada: Bioethics, Innovation and Policy Integration Division, 71pp.
7. Bubela Tania, **E. Richard Gold**, Jean-Frederic Morin, et al. *Evidence and Background Information to Inform Canada’s Approach to Public Health and Intellectual Property Issues in International Fora* (2010) Report to Health Canada’s International Affairs Directorate (IAD) 94pp.
8. **Gold, E. Richard** et al, *Toward a New Era of Intellectual Property: from confrontation to negotiation* (Montreal: The Innovation Partnership, 2008)
9. **Gold, E. Richard**, Tina Piper, Jean-Frédéric Morin, Karen L. Durell, Julia Carbone and Elisa Henry, *Preliminary Legal Review of Proposed Medicines Patent Pool,* 2007 report for UNITAID.
10. **Gold, E. Richard**, Matthew Herder, and Michel Trommetter, *The Role of Biotechnology Intellectual Property Rights in the Bioeconomy of 2030*, 2007 report for the OECD.
11. Herder, Matthew and **E. Richard Gold,** *Intellectual Property Issues in Biotechnology: Health and Industry*, 2007 report for the OECD.
12. Piper, Tina, **E. Richard Gold,** and Olivier Plessis, *A Study and Recommendations Regarding Intellectual Property Policies in the Not-for-Profit Cancer Research Sector,*  2007 report for the Canadian Breast Cancer Foundation, Ontario Region.
13. **Gold, E. Richard**, et al., Recommendations for Canadian Genetic Patents and Health Care: An International Comparison of Patent Regimes in Canada and its Major Trading Partners (2005) for the Canadian Biotechnology Advisory Committee.
14. Bernier, Louise, Karen L. Durell, and **E. Richard Gold,** *WHO Literature Review on the Impact of Gene Patents on Access to Genetic Technologies and Services: View from Developing Countries,* 2004 report for the World Health Organization
15. **Gold, E. Richard**, and Lorraine Sheremeta, *The Research or Experimental Use Exception: A Comparative Analysis* (2004) report for Health Canada
16. **Gold, E. Richard** and Timothy Caulfield, Human Genetic Inventions, Patenting and Human Rights (2004) for Canada Department of Justice
17. **Gold, E. Richard** (rapporteur), “Report on President/CEO Briefing to CBAC” (2001) for the Canadian Biotechnology Advisory Committee.
18. **Gold, E. Richard** (rapporteur), “Report on NGO Hearing before CBAC” (2001) for theCanadian Biotechnology Advisory Committee.

***Contributions to governmental reports***

1. Organisation for Economic Cooperation and Development, Guidelines on the Licensing of Genetic Inventions, 2006
2. Ontario Ministry of Health and Long-Term Care, Genetics, Testing & Gene Patenting: Charting New Territory in Healthcare, 2002.
3. Canadian Biotechnology Advisory Committee, Patenting of Higher Life Forms and Related Issues, 2002.

***Comments/Blogs (recent)***

1. Ali-Khan, Sarah and **Gold, E. Richard**, “Contracting to counter gene patents – a 21st Century solution to access and innovation” (May 22, 2017), *Harvard Law’s Bill of Health*, http://blogs.harvard.edu/billofhealth/2017/05/22/contracting-to-counter-gene-patents-a-21st-century-solution-to-access-and-innovation/.
2. **Gold, Richard**, “NAFTA patent ruling a big victory for Canadian innovation” (April 6, 2017) *The Globe and Mail* <http://www.theglobeandmail.com/report-on-business/rob-commentary/nafta-patent-ruling-a-big-victory-for-canadian-innovation/article34617647/>
3. **Gold, E. Richard**, “In the Trump era, Canada can be a beacon for innovations” (November 18, 2016) *The Globe and Mail* [*http://www.theglobeandmail.com/report-on-business/rob-commentary/in-the-trump-era-canada-can-be-a-beacon-for-innovators/article32898581/*](http://www.theglobeandmail.com/report-on-business/rob-commentary/in-the-trump-era-canada-can-be-a-beacon-for-innovators/article32898581/)
4. **Gold, E. Richard**, “We need to be training Canadians in the modern ideas economy” (July 12, 2016) *The Globe and Mail*, http://www.theglobeandmail.com/report-on-business/rob-commentary/we-need-to-be-training-canadians-in-the-modern-ideas-economy/article30858981/
5. **Gold, E. Richard**, “Getting Patents Right” (March 23, 2015), *National Post,* [*http://news.nationalpost.com/full-comment/richard-gold-getting-patents-right*](http://news.nationalpost.com/full-comment/richard-gold-getting-patents-right)
6. **Gold, E. Richard**, “How the Grinch Stole Chocolate” (December 19, 2007) *The Globe and Mail, http://www.theglobeandmail.com/opinion/how-the-grinch-stole-chocolate/article1092001/*
7. **Gold, E. Richard**, “A Bitter but Necessary Pill to Swallow” (June 21, 2006) *The Globe and Mail*.
8. **Gold, E. Richard**, “Monsanto’s Gain is Everyone Else’s Pain” (May 24, 2004) *The Globe and Mail.*
9. **Gold, E. Richard**, “Building a Better Patent Law” (May 17, 2002) *The Globe and Mail.*
10. **Gold, E. Richard**, Timothy Caulfield, Bartha Maria Knoppers, Peter Bridge, Genevieve Cardinal, Erika Duenas, and Lori Sheremeta, "Ottawa must Act on DNA Patents." (December 15, 2001) *The Gazette*, B7.
11. Timothy Caulfied and **Gold, E. Richard** "The Dark Side of Gene Patenting" (November 21, 2001) *The Ottawa Citizen* A19.
12. **Gold, E. Richard**, “My Body, Your Patent” (October 29, 2001), *The Globe and Mail.*
13. **Gold, E. Richard**, “Myths and Misdemeanours of Gene Patents” (September 28, 1999) *The Ottawa Citizen* A19.

***Other***

1. Welling, Bruce, Lionel Smith, **E. Richard Gold,** and Leonard I. Rotman, *Canadian Corporate Law: Cases, Notes & Materials, 2nd Ed.* (Toronto: Butterworths, 2001).
2. **Gold, E. Richard,** *Handbook on Biological Property* (Washington, D.C.: Einstein Institute for Science, Health & the Courts, 2001).

**APPENDIX B**

**RESEARCH GRANTS**

**Healthy Brains for Health Lives**

Chair, 2016, Open Science Monitoring and Evaluation Committee, $84 million, 7 years

**Canada First Research Excellence Fund**

This interdisciplinary program in neuroscience aims at delivering implementable, clinically effective outcomes in brain and mental health by shifting the paradigm in our understanding of brain disorders and university-industry partnerships, notably through open science.

**Intellectual Property and Innovation**

Principal Investigator, 2016, $23,530 cash, 1.5 years, approximately $125,000 in-kind. Total budget approximately $148,530.

**Centre for International Governance Innovation**

This funding supports my organization, videotaping and policy essays investigating various aspects of innovation and intellectual property.

**Genomics and personalized health Ge3LS Network**

Co-Applicant, 2016, Genome Canada: $998,473; Total budget: $1,996,945, 2.5 years

**Genome Canada**

This network grant advances translation of GELS research into policy in the field of personalized medicine.

**Montreal Neurological Institute Open Science Project**

Principal Investigator, 2015, $20,0000, 6 months

**Montreal Neurological Institute**

We investigate the meaning of open science to researchers and students working at the Montreal Neurological Institute, their concerns over the effect of open science on their work and propose principles to advance open science within the context of the Institute.

**BIOSMART: Managing the transition to a "smart" bioeconomy**

Partner, 2015, 39,960,000 NOK

**The Research Council of Norway**

BIOSMART promotes a "smart" transition by conducting a major foresighting exercise on stakeholders in the bioeconomy. An initial extensive foresighting process will cover 1500 businesses from the farming, forestry, fisheries, bio-science and industry sectors to develop separate industry scenarios of bioeconomic development.

**An Intellectual Property Index:  Creating a firm foundation for transdisciplinary study, policy-making and business strategy**

Principal Investigator, 2013,  $139.980,00, 3 years (extended by one year)

**Social Sciences and Humanities Research Council, Insight Grant**

This project brings together a multidisciplinary team to construct and validate an index of intellectual property rights protection around the world.

**PACE - 'Omics: Personalized, Accessible, Cost-Effective applications of 'Omics technologies**

Co-Investigator and Co-Lead of Intellectual Property Theme, grant co-PIs, Chris McCabe & Tania Bubela, 2013, $4,502,080, 4 years

**Genome Alberta** and **Genome Quebec**

This multi-disciplinary team investigates how best to connet those who innovate in respect of personalized medicine with those who conduct technology assessment. My role on the grant is to investigate innovation systems, intellectual property and to lead knowledge translation activities.

**Enhancing Translational Stem Cell Research: Innovative Models for Multi-Sectoral Collaboration**

Co-Investigator, grant PI Tania Bubela, 2011, $350,000, three and a half years

**Stem Cell Network**

We investigate, in this interdisciplinary project, model structures to enhance collaboration between public and private sector researchers working on new health technologies.

**Building Social Capital for Health Innovation**

Principal Investigator, 2013, $113,000, 1.5 years

**Grand Challenges Canada: Stars in Global Health**

I lead a team that will identify technology developed in Kenya with the potential of contributing to increased health in the region. We will assess the technology both for its technical merits and its contribution and will assist in gaining intellectual property rights.

**International Bar-Code of Life (iBOL) GE³LS Working Group**

Co-Investigator and Project Leader, grant held by David Castle, 2010, $999,259, five years

Will support one doctoral student at McGill

**Genome Canada**

This project involved conducting a patent landscape with respect to bar-code technology – used to identify species and pathogens – and develop models through which to make the technology accessible.

**Value Addition to Genomics and GE³LS (VALGEN)**

Co-Investigator and Member of the Scientific Management Executive Committee, grant held by Peter Phillips & David Castle, 2009, $5,413,000, four years

Will support 2 doctoral students at McGill

**Genome Canada**

The project provides a single platform for GELS research in the ag-biotechnology domain

**The functionality of the “three-step test”**

Co-Investigator, grant held by Edson Rodrigues Jr., 2008, $75,000, one year

1 doctoral student at McGill

**International Development Research Centre (IDRC)**

The project aims at investigating the research exception under patent law in light of international trade agreements.

**Eastern Africa Intellectual Property Training**

Principal Investigator, 2007, $50,000, one year

Supported 1 doctoral student at McGill

**Foundation for Sustainable Enterprise and Development**

This grant supported training of senior health and agricultural researchers in Eastern Africa as well as government policy-makers on intellectual property and technology transfer. The aim of the training was for the participants to carry out studies of the intellectual property practices in their home institutions.

**Regenerative Medicine and Ethics Network (RMEthNet)**

Co-applicant, grant led by Abdallah S. Daar, 2007, $301,000, three years

Supported 1 doctoral student at McGill

**Canadian Institutes for Health Research**

Multi-institutional and interdisciplinary team examining ethical and legal issues related to regenerative medicine.

**Intellectual property governance and non-state actors: the case of Bill C-9**

Principal Investigator, 2006, $175,042, two years

22 students at McGill (1 post-doc, 2 doctoral, 19 undergraduate) – 3 undergraduate students at U of Alberta – 1 doctoral student at U of Toronto

**Canadian Institutes for Health Research**

Study of the role of non-state actors (NGOs and industry groups) in having Member States of the WTO agree to paragraph 6 of the Doha Agreement and subsequent passage of Bill C-9 in Canada that gave effect to this paragraph.

**Inventors as investigators: an empirical study of patent holding and ethics in human gene transfer research**

Co-Applicant, grant led by Jonathan Kimmelman, 2006, $104,826, two years

1 doctoral student at McGill

**Canadian Institutes for Health Research**

Study examining whether clinical investigators disclose conflicts-of-interest related to patent holdings.

**Performance, Modélisation, Coordination et Transformation des Entreprises de Biotechnologie**

Co-Investigator, grant held by Martin Cloutier, 2006, $482,880, four years

**Fonds québécois de la recherche sur la société et la culture**

A grant to support the creation of a new research group to model the biotechnology industry.

**Mobilising Health Knowledge and Technology in Latin America**

Co-Principal Investigator with Maristela Basso, 2006, $15,000, one year

**International Development Research Centre, Teasdale-Corti Development Grant**

This grant was awarded to develop a full grant application that combines research, capacity-building and knowledge mobilisation in the health care sector in developing countries.

**Advanced Food and Materials Network (AFMNet)**

Project Leader, grant led by Ricky Yada, 2003, $22.2 million, two and a half years

2 graduate and 1 undergraduate students at McGill

**Network of Centres of Excellence**

This project investigated intellectual property and intellectual property management issues relating to ag-biotechnology in multi-institutional project.

**Genomics and global health: Developing a global CIHR network to address ethical, policy and regulatory issues**

Co-Applicant, grant led by Abdallah S. Daar, 2003, $62,700, one year

**Canadian Institutes for Health Research**

This project built a network on ethical and policy issues related to genomics globally.

**Legal Models of Biotechnological Intellectual Property Protection: A Transdisciplinary Approach**

Principal Investigator, 2003, $2,989,500, five years

28 undergraduate, 9 graduate students and 14 visiting scholars at McGill, 2 graduate students and 1 post-doc at UQAM, 1 graduate student at U of Alberta, 1 graduate student at U of Minnesota, 1 post-doc at U of Ottawa

**Social Sciences and Humanities Research Council, Initiative on the New Economy, Collaborative Research Initiative**

Interdisciplinary grant to investigate alternative intellectual property regimes with respect to agricultural biotechnology.

**Translating genetic discoveries into appropriate health policy and services: enhancing research capacity and developing an interdisciplinary approach**

Co-Applicant, grant led by Brenda Wilson and Timothy Caulfield, 2003, $998,665, four years

**Canadian Institutes for Health Research**

Interdisciplinary team grant investigating the impact of genetic innovation on health policy.

**Bridging the Emerging Genomics Divide**

Co-Investigator, grant led by Peter Singer, 2002, $2.83 million, five years

**Genome Canada**

A multi-disciplinary project investigating ways to avoid creating a ‘genomics divide’ between high-income and low-income countries.

**Modules for the New Economy**

Co-Principal Investigator with David Lametti, 2002, $8,000, one year

Supported one undergraduate law student at McGill

**Fondation du barreau du Québec**

Project to identify case studies that will eventually be used to create a series of published, widely available and independent modules that can be incorporated into existing law school, bar formation, or continuing education courses.

**Reconciling growth with ethics: Models of intellectual property protection for biotechnological innovation**

Principal Investigator, 2002, $288,626, three years

1 graduate and 1 undergraduate student at McGill

**Canadian Institutes for Health Research**

Project to develop and critique models of intellectual property relating to biotechnological innovation in the health care field.

**Canadian Program in Genomics and Global Health**

Investigator, grant led by Peter Singer, 2001, $7.2 million, five years

**Genome Canada**

A multi-disciplinary project investigating ways that the developing world can benefit from biotechnology.

**APPENDIX C**

**SELECTED PRESENTATIONS**

***Tiered Governance for Food and other Wicked Problems***

Online presentation, April 27, 2017

**The Convergent Innovation Webinar Series Pulse Program**

I discuss the governance of public-private partnerships aimed at resolving complex social problems.

***The Open Road of Open Science***

Frankfurt, Germany, April 24, 2017

**Frankfurt Open Access/Open Science Symposium**

I discussed how open science can both accelerate research and bolster innovation in the life sciences.

***Jump Starting Neurological Research and New Models of Collaboration***

Boston, MA, February 17, 2017, with Guy Rouleau

**American Association for the Advancement of Science Annual Meeting**

Guy Rouleau, Director of the Montreal Neurological Institute, and I presented the Open Science Initiative at the Institute.

***The Context of Innovation***

Montreal, Quebec, November 19, 2016

**Innovation in Context Workshop**

This introductory keynote highlights the social context in which innovation is developed and firms developed. I organized this international workshop.

***Predatory IP Law and Canadian Innovation***

Montreal, Quebec, November 2, 2016

**The Social Costs of Innovation: Law, Society, and the Greater Good**

This presentation focused on the distribution between states of costs and benefits of intellectual property systems and its implications for innovation and intellectual property policy.

***Open Science and ethical transparency***

Montreal, Quebec, October 27, 2016

**IRB Data Sharing Forum**

I discussed the effect of open science on ethical concerns such as consent and on monitoring research on an ongoing basis.

***Current and Future Approaches to Governance: Open Science***

Washington DC, September 14, 2016

**OECD Workshop on Neurotechnology and Society: Strengthening Responsible Innovaiton in Brain Science**

I discussed how open science can contribute to identifying ethical concerns early in research.

***The IP and Innovation Landscape in the Global Economy: Canada in a Comparative Perspective***

Toronto, September 8, 2016

**Thinking Through IP Issues: Improving Ontario’s Innovation Performance**

In this workshop co-organized by the Government of Ontario and the Centre for International Governance Innovation, I spoke about the challenges in aligning Canadian innovation policy with intellectual property policy.

***Intellectual Property, Innovation and Building Local Innovation Capacity***

Trondheim, Norway, August 24, 2016

**Biosmart Workshop on Property and Intellectual Property**

I discussed how countries and regions could create local innovation capacity through building open collaborations

***TransPacific Partnership Town Hall***

Montreal, June 6, 2016

**Town Hall Organized by Minister of International Trade**

I provided an introduction to intellectual property issues covered by the proposed TransPacific Partnership Agreement at the request of the Minister of International Trade.

***Open Science, IP and Converging Technologies***

Washington DC (by video), May 26, 2016

**Biotechnology, Nanotechnology and Converging Technologies Working Party of the Organisation for Economic Co-operation and Development**

I spoke about developing local innovation capacity through the use and deliberate avoidance of intellectual property rights.

***Innovating Innovation Policy***

Montreal, QC, February 23, 2016

**Innovation and Intellectual Property Think Ahead**

In this address, I discussed how Canada suffers from a lack of innovation policy and over-emphasis on intellectual property.

***Impact of IP on Innovation and Translation***

Montreal, QC, February 11, 2016

**Commercialization of NIPT Workshop**

This presentation focuses on how intellectual property affects the development of non-invasive prenatal testing in Canada.

***IP and Trade: much ado but innovation***

Montreal, QC, January 29, 2016

**Understanding the TPP: IP Protection and Investment Protection, CIPP and CIGI**

I discussed the link between trade and intellectual property policy, showing how the combination inhibit business innovation.

***IP and Trade: much ado but innovation***

Toronto, ON, January 14-15, 2016

**The Trans Pacific Partnership: Options for Canada and the World, Munk School of Global Affairs**

I discussed the link between trade and intellectual property before the federal Minister of Trade and other select guests.

***Governing Research: Design and Governance***

Washington, DC, December 1-3, 2015

**International Summit on Human Gene Editing: A Global Discussion, National Academy of Science, National Academy of Medicine, the Royal Society and the Chinese Academy of Science**

I discussed how open science could help mitigate concerns over the use of human gene editing tools in front of an international audience.

***Building a Framework for Open Science at the MNI***

Esterel, QC, November 13, 2015

**Montreal Neurological Institute Annual Retreat**

I presenting findings of a qualitative study of researchers on their attitudes and concerns about open science.

***Changing the landscape of gene patents: social science at work***

Edmonton, AB, June 18, 2015

**Genomics & Personalized Medicine - Health Policy and Barriers to Adoption**

I discussed how social science research interacts with real time decision making through a discussion of how researchers can contribute to a test case before the courts.

***Intellectual Property in the National Centres of Excellence: Too limited an approach to knowledge translation***

Ottawa, ON, March 31, 2015

**National Centres of Excellence Annual Meeting**

I discussed how research granting agencies place too much emphasis on intellectual property as a means of knowledge translation rather than a broader range of mechanisms.

***Patenting Genetic Materials: Biotechnology and Intellectual Property Law***

Montreal, QC, March 18, 2015

**Patenting Human Genes, McGill Faculty of Law**

I discussed a Canadian test case on the patentability of human genes and associated methods.

***Collaborative Research Consortia: When are They more Effective than Market Contracting?***

Toronto, ON, November 6-7, 2014

**Driving Regenerative Medicine to the Market and Clinic**

I organized and chaired a discussion of how to best structure collaborative research so as to spur innovation.

***Future directions in Canadian science, technology and innovation policy***

Ottawa, ON, September 23, 2014

**The Future of Canada’s Bioscience and Agricultural Innovation**

I chaired a panel examining policies needed to advance Canadian innovation in the biosciences and agriculture.

***Secondary Use Patents: An international and Canadian perspective***

Washington, DC, June 5, 2014 (via teleconference)

**Secondary Use Pharmaceutical Patents: Litigation and Trade Policy Briefing**

This policy briefing, jointly sponsored by American University and Public Citizen, aimed at informing US policy-makers on the current state and law and associated policy with respect to second use claims over pharmaceutical products.

***Science and the Courts***

Washington, DC, March 13-14, 2014

**The Future of Gene Patents – making sense of the Supreme Court’s decision in the Myriad case**

I facilitated a discussion among a leading geneticist, patent expert and judge of the United States Court of Appeals for the Federal Circuit on the intersection of science and law with a particular focus on decisions related to the patenting of genes.

***Myriad (Gene Patent) Problems? Past, Present and Future***

Halifax, NS, February 13, 2014

**Schulich School of Law, Law and Technology Institute**

I discussed the holding and implications of the US Supreme Court decision in AMP v. Myriad and its implications for Canada.

***Is Canada out of Step?***

Toronto, Canada, 2013

**University of Toronto Patent Law Colloquium**

In the context of a panel discussing how Canadian patent law compares to those in other countries, I discussed the lack of any formal or informal standard with respect to substantive patent law and what this implies for trade disputes concerning that law.

***A World of Confusion: Patent Law and the Life Sciences***

Toronto, Canada, 2013

**Canadian Science Policy Conference**

I highlighted how Canadian law relating to patentable subject-matter has been put in doubt by developments beyond Canada’s borders, namely public interest litigation in the US, Australia and Europe.

***Myriad and Beyond: The fallout of the US Supreme Court decision***

Vancouver, Canada, 2013

**UBC Science and Technology Studies Colloquium**

I discussed the background to the US decision in AMP v. Myriad and how that decision was viewed and understood by various audiences.

***Collaborative Mechanisms re Synthetic Biology***

Edinburgh, Scotland, 2013

**Synthetic Biology, Innovation and Intellectual Property: Toward a UK Strategy**

I examined the role of collaborative research in life science research, its justifications and concerns.

***International Policy Dimensions of Gene Patents***

Cold Spring Harbor, USA, 2013

**Genes & Diagnostics: A Myriad of Issues in Biotech IP**

In the context of an international discussion of human gene patents, I provided a discussion of the international policy context, focusing on Canada, Europe and Australia.

***Designing, Building and Managing Research Collaborations***

Bellagio, Italy, 2012

**Bellagio Workshop on Convergent Innovation**

I discussed how to design and manage collaborative scientific research projects, drawing on theory from economics and innovation studies.

***Échange et exclusivité : la nouvelle propriété industrielle***

Gréoux-les-bains, France, 2012

**Université européenne d’été de l’IHEST 2012: Sciences, éthique et droit : dynamique et concurrence des normes**

As part of a week-long discussion of the role of norms in science, ethics and law, I discussed the role of norms as sometimes supplementing and sometimes supplanting legal norms relating to intellectual property.

***The State of Canadian Patent Law***

Ottawa, Canada, 2012

**Standing Committee on Industry, Science and Technology**

I was invited to present my views on the current state of Canadian patent laws, its compliance with international norms and recommendations to improve it.

***Intellectual Property and Human Rights: A Heterodox Approach***

Toronto, Canada, 2012

**2012 National Health Law Conference: Global Health Challenges and the Role of Law**

I discussed the intersection of intellectual property rights and human rights, critiquing current approaches that place both at the same institutional (international) and normative (fundamental rights) level.

***Plenary Debate Session: Owning the Genome: The Patenting and Licensing of Genes and Their Impact on Medical Genetics***

Montreal, October, 2011

**International Congress on Human Genetics 2011/American Association of Human Genetics Annual Meeting 2011**

This plenary session, before over 2,500 participants, discussed the benefits and dangers of patenting human genetic material.

***Genomics Research and Intellectual Property***

Ottawa, April 2011

**Genome Canada**

This presentation discussed the need for intellectual property management policies within Genome Canada and other funding agencies in Canada.

***New Mechanisms for Collaboration***

Ottawa, April 2011

**Canadian International Council: Intellectual Property Workshop**

This workshop of experts in intellectual property policy and business discussed how Canada can develop an intellectual property policy that furthers Canadian economic and social interests.

***A qui appartiennent les œuvres et inventions de vos salariés? Regard de l’Amérique du Nord***

Paris, February 2011

**Gide Loyrette Nouel breakfast conference**

In this conference aimed at the business community in Paris, I discussed US and Canadian law on employee rights in works and inventions.

***Knowledge Networks and Markets in the Life Sciences***

Banff, January 2011

**VALGEN IP Workshop**

Based on a report I completed for the OECD, I presented the current state of knowledge on knowledge networks and markets.

***Technology Transfer, Universities and Eco-Innovation***

Paris, November 2010

**University of Paris Sud**

In this seminar, I discussed how universities and industry can take advantage of new models of public-private collaborations.

***Intellectual Property and Synthetic Biology***

Montreal, September 2010

**Science Café public talk**

***Development and Innovation***

Toronto, Canada, 2010

**Munk Centre: Governing Global Development:** **The Role of the G8 in Health, Nutrition and Food**

***Beyond Open Source: Patents, Biobanks and Sharing***

Trento, Italy, 2010

**University of Trento: Comparative Issues in the Governance of Research Biobanks**

***Intellectual Property: Why it Matters to Global Health***

Montreal, Canada, 2010

**McGill Colloquium on Health and Law**

***Toward a new era of intellectual property: Building collaborations as a means to access knowledge***

Ottawa, Canada, 2009

**International Development Research Centre: Accessing Patented Knowledge for Innovation**

***Toward a new era of intellectual property: “facts’ in light of international trends and pressures***

Montreal, Canada, 2009

**National Judicial Institute: Federal Court Annual Education Seminar**

***IPRs and Innovation Governance***

Toronto, Canada, 2009

**Conference Board of Canada: Intellectual Property Rights: Innovation and Commercialization in Turbulent** **Times**

***Toward a new era of intellectual property: the need for research partnerships***

Toronto, Canada, 2009

**York University: Entrepreneurship and Commercialization in Biomedical Science**

***Toward a new era of intellectual property: capacity building from the bottom up***

Montreal, Canada, 2009

**Building and Maintaining Sustainable Global Health Partnerships**

***Translating Research into Policy: technology transfer***

Toronto, Canada, 2009

**Universities, Innovation and Global Medicine Access**

***Toward a new era of intellectual property: from confrontation to negotiation***

Barbados, 2009

**SGC Barbados Epigenetics Probe Meeting**

***Innovation and the failure to collaborate***

Boston, USA, 2009

**The Impact of Patent Law on the Economy: Stimulus or Impediment?**

***Toward a New Era in Intellectual Property: Implications and Opportunities for CIPO***

Ottawa, Canada, 2009

**Canadian Intellectual Property Office**

***Innovation, propriété intellectuelle et transfert de technologie: vers de nouveaux modèles collaboratifs***

Montreal, Canada, 2009

**La Direction du développement économique et urbain de la Ville de Montréal**

***The Patent Paradox: Patents and Access to Medical Discoveries***

Collingwood, Canada, 2008

**Georgian Triangle Lifelong Learning Institute: Ethical Dilemmas of the New Genetics**

***La propriété intellectuelle confrontée aux données économiques et politiques***

Paris, France, 2008

**Propriété intellectuelle, biotechnologies, et enjeux sociaux à l’heure de la globalization**

***Myriad Genetics: In the eye of a policy storm***

Paris, France, 2008

**Propriété intellectuelle, biotechnologies, et enjeux sociaux à l’heure de la globalization**

***Innovation, Intellectual Property, and Collective Value Creation***

Montreal, Canada, 2008

**From Crisis to a New Convergence of Agriculture, Agri-food and Health**

***From Anarchy to Organised Chaos***

Montreal, Canada, 2008

**In Support of A Whole-of-Society Approach to Population Health and Global Health Diplomacy for Chronic Disease Prevention**

***Toward a new era of intellectual property: aligning competition and IP policy***

Montreal, Canada, 2008

**Innovative to abuse? Exploring the interactions between intellectual property and competition law**

***From Confrontation to Negotiation: Toward a New Era of Intellectual Property***

Washington, DC, USA, 2008

**Policy briefing on Capitol Hill**

***From Confrontation to Negotiation: Toward a New Era of Intellectual Property***

London, UK, 2008

**Science Media Centre**

***From Confrontation to Negotiation: Toward a New Era of Intellectual Property***

Ottawa, Canada, 2008

**Policy briefing**

***Transfert technologique & propriété intellectuelle: le contexte québécois***

Quebec, Canada, 2008

**Transfert technologique, commercialisation et propriété intellectuelle,**

**Symposium sur les Créneaux d’excellence québécois et les Pôles de compétitivité français**

***Patents and Biotechnology: Where are we? Where are we going?***

Montreal, Canada, 2008

**Montreal InVivo Breakfast Seminar**

***Industry/Agriculture Intellectual Property***

Paris, France, 2008

**OECD International Futures Program**

***Health Intellectual Property***

Paris, France, 2008

**OECD International Futures Program**

***Intellectual Property and Biotechnology***

Ottawa, Canada, 2008

**Carleton University Panel Discussion on Valuing Life: Futurity, Regulatory Regimes and Contemporary Biosociality**

***Myriad Genetics: In the eye of a policy storm***

Toronto, Canada, 2007

**University of Toronto**

***Innovation Systems***

Beijing, China, 2007

**Global Forum on Health Research**

***Canada’s Access to Medicines Regime: Politics over Praxis***

Beijing, China, 2007

**Global Forum on Health Research**

***Intellectual Property Policy: The work of the CIPP and the case of Myriad Genetics***Tokyo, Japan, 2007

**Research Office on Economy, Trade and Industry, Japanese Parliament**

***An Anti-Retroviral Medicines Patent Pool: A partial solution***

Tokyo, Japan, 2007

**National Graduate Institute for Policy Studies**

***Moving forward on suggested IGWG actions related to IP and Health***

Ottawa, Canada, 2007

**Canada’s Managing IP for Health Technical Workshop**

***Genetic Data and Intellectual Property: Levels of Data and of Protection***

Trento, Italy, 2007

**University of Trento conference on Genetic Data: Opportunity and Threats**

***Canada’s Access to Medicines Regime: Policy over Praxis***

Edinburgh, Scotland, 2007

**University of Edinburgh**

***Preliminary Legal Review of a Medicines Patent Pool***

Geneva, Switzerland, 2007, with Jean-Frederic Morin

**UNITAID Board Meeting**

***General Overview of the International Gene Patents and Licensing Practices Landscape***

Washington, DC, USA, 2007

**Secretary of Health’s Advisory Committee on Genetics, Health and Society**

***BRCA Testing in Canada***

Washington, DC, USA, 2007

**Secretary of Health’s Advisory Committee on Genetics, Health and Society**

***Legal Interpretation and Ontologies: Law, institutions and practices and the case of Myriad Genetics***

Trento, Italy, 2007

**University of Trento**

***Domestic and International Canadian Policy re IP and Access to Medicines***

Ottawa, Canada, 2007

**Health Canada: Trade and Health Workshop**

***Compulsory Licensing and Competition***

Ottawa, Canada, 2007

**Competition Bureau: IP/Competition Policy Symposium**

***Knowledge and Property: Unraveling the relationship***

Exeter, UK, 2007

**University of Exeter: Governing Genomics Conference**

***Of Mice and Women: Looking for new business models***

Durham, USA, 2006 with Tania Bubela

**Duke University: Center for Genome, Ethics, Law and Policy**

***Biotech Patents: A rational policy response***

Edmonton, Canada, 2006

**Health Law Institute Seminar Series 2006/2007**

***Myriad Genetics: Case study***

Edmonton, Canada, 2006 with Julia Carbone

**Workshop on Policy Response to Breast Cancer Patents**

***Droits de propriété intellectuelle et droit de la concurrence : Convergence ou Divergence ?***

Paris, France, 2006

**Cour de Cassation: Droits de propriété intellectuelle : Approches juridiques et économiques.**

***Challenges in Innovation***

Cairo, Egypt, 2006

**Global Forum on Health Research**

***The Latin American Consortium on Biotechnology IP***

Buenos Aires, Argentina 2006

**Intellectual Property Biotechnology Capacity and Development**

***From Research to Policy: the work of the Intellectual Property Modeling Group***

Durham, USA, 2006

**Duke University, School of Law**

***Comparative Intellectual Property Issues in Biotechnology***

Victoria, Canada, 2006

**Food, Health and Biotechnology: Consumer and Social Issues in Canada’s New Food and Health Product Industries**

***From Research to Policy: the work of the Intellectual Property Modeling Group***

Ottawa, Canada, 2006

**Canadian Intellectual Property Office**

***Cutting Edge IP Law***

St. John’s, Canada, 2006

**Canadian Bar Association Canadian Legal Conference**

***Biotechnology and Boundaries***

Trento, Italy, 2006

**Life, Technology, and the Law**

***Rational Policy Responses?***

Banff, Canada, 2006

**Workshop: Biotechnology Patents and Policy: What’s the Evidence?**

***De la recherche à la décision politique : l’expérience du groupe de modélisation en propriété intellectuelle***

Montreal, Canada, 2006

**Colloque ACFAS 2006**

***Implementing the OECD Guidelines in Canada***

Vancouver, Canada, 2006

**Health Canada Symposium on Human Genetics Licensing**

***IP as Place Brand***

Montreal, Canada, 2006

**McGill University Meredith Memorial Lectures**

***A Private Law Perspective on 20th Century Monetary History***

Claremont, US, 2006

**Bretton Woods Revisited Workshop**

***Patent Scope in Genes: A comparative analysis of scope***

London, UK, 2005, with Karen L. Durell

**Patenting Lives Conference**

***Commercializing University Research: Beyond economic incentives***

St. Louis, US, 2005

**Conference on Commercializing Innovation**

***The Public Face of IP Management***

Florence, Italy, 2005

**Centre for Intellectual Property Policy**

***Essential Medicine, Gene and Stem Cell Patents***

Garrison, NY, 2005

**Hastings Centre for Bioethics**

***Round Table: Intellectual Property and Biotechnology in respect of developing countries***

Buenos Aires, Argentina, 2005

**University of Buenos Aires**